Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) have been given a consensus recommendation of “Buy” by the twenty-seven brokerages that are covering the stock. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and twenty-two have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $132.33.

Several analysts have recently issued reports on the stock. Jefferies Group restated a “buy” rating and set a $150.00 target price on shares of Zimmer Biomet Holdings in a research report on Monday, August 8th. BMO Capital Markets restated a “buy” rating and set a $146.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 29th. JPMorgan Chase & Co. upped their target price on shares of Zimmer Biomet Holdings from $134.00 to $148.00 and gave the company an “overweight” rating in a research report on Friday, July 29th. JMP Securities increased their price objective on shares of Zimmer Biomet Holdings from $131.00 to $145.00 and gave the stock a “market outperform” rating in a research report on Friday, July 29th. Finally, SunTrust Banks Inc. began coverage on shares of Zimmer Biomet Holdings in a research report on Thursday, August 11th. They issued a “buy” rating and a $155.00 price objective on the stock.

Shares of Zimmer Biomet Holdings (NYSE:ZBH) opened at 124.97 on Thursday. The firm’s 50-day moving average price is $128.65 and its 200 day moving average price is $119.01. The company has a market capitalization of $25.00 billion, a PE ratio of 114.13 and a beta of 0.95. Zimmer Biomet Holdings has a 52-week low of $88.27 and a 52-week high of $133.19.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its earnings results on Thursday, July 28th. The company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.97 by $0.05. The firm had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.90 billion. Zimmer Biomet Holdings had a net margin of 1.68% and a return on equity of 16.12%. The business’s revenue was up 65.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.58 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings will post $7.97 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 23rd will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend is Wednesday, September 21st. Zimmer Biomet Holdings’s payout ratio is currently 157.38%.

In other news, insider Stuart G. Kleopfer sold 533 shares of the company’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $132.71, for a total value of $70,734.43. Following the completion of the transaction, the insider now owns 6,397 shares in the company, valued at approximately $848,945.87. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Daniel P. Florin sold 15,000 shares of the company’s stock in a transaction on Monday, July 11th. The shares were sold at an average price of $124.98, for a total transaction of $1,874,700.00. Following the completion of the transaction, the chief financial officer now owns 16,983 shares of the company’s stock, valued at approximately $2,122,535.34. The disclosure for this sale can be found here. Corporate insiders own 1.22% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of ZBH. Heritage Investors Management Corp boosted its stake in shares of Zimmer Biomet Holdings by 2.9% in the first quarter. Heritage Investors Management Corp now owns 110,959 shares of the company’s stock worth $11,832,000 after buying an additional 3,108 shares in the last quarter. Exxonmobil Investment Management Inc. TX boosted its stake in shares of Zimmer Biomet Holdings by 13.6% in the first quarter. Exxonmobil Investment Management Inc. TX now owns 43,570 shares of the company’s stock worth $4,646,000 after buying an additional 5,202 shares during the last quarter. Capstone Asset Management Co. boosted its stake in shares of Zimmer Biomet Holdings by 4.8% in the first quarter. Capstone Asset Management Co. now owns 18,877 shares of the company’s stock worth $2,013,000 after buying an additional 870 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in shares of Zimmer Biomet Holdings by 28.5% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 44,124 shares of the company’s stock worth $4,705,000 after buying an additional 9,799 shares during the last quarter. Finally, DnB Asset Management AS boosted its stake in shares of Zimmer Biomet Holdings by 503.6% in the first quarter. DnB Asset Management AS now owns 60,408 shares of the company’s stock worth $6,441,000 after buying an additional 50,400 shares during the last quarter. Institutional investors and hedge funds own 88.42% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.